We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 26, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Illumina, Inc. (ILMN - Free Report) , Ultragenyx Pharmaceutical Inc. (RARE - Free Report) , Xenon Pharmaceuticals Inc. (XENE - Free Report) , Vanda Pharmaceuticals Inc. (VNDA - Free Report) and Pharming Group N.V. (PHGUF - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
On Jul 24, President Trump tweeted protectionist rhetoric once again, claiming that “Tariffs are the greatest!” He believes that they are an effective bargaining tool which can force countries to negotiate more equitable trade agreements. At this point, the Trump administration has imposed tariffs on Chinese imports worth $34 billion and more such levies are likely to follow.
Though markets are now choosing to focus on the ongoing earnings, they have been rattled by such moves in the past. It is unlikely that this trend will be disrupted in the near future. Investors, are, therefore, constantly on the lookout for investments which can provide both protection and profits in such a scenario.
Incidentally, biotech stocks are largely resilient to trade-related disruptions. Healthcare is a non-tradeable activity and its fortunes are dictated by the furious pace of advancements in this area. Given the current market backdrop, it makes good sense to invest in biotech stocks at this point.
Trump Maintains Protectionist Stance
Trump’s latest remarks are similar to tweets made earlier in March, when he claimed that “trade wars are good, and easy to win.” Apart from the tariffs imposed on $34 billion worth of Chinese goods, the Trump administration will also shortly impose tariffs on goods worth an additional $16 billion. Trump is also considering imposing tariffs on an additional $200 billion of Chinese imports.
And that’s not all. In an interview with CNBC on Jul 19, the President said that he may even impose tariffs on an additional $505 billion of Chinese imports. Meanwhile, Trump is slated to meet European Commission President Jean-Claude Juncker on Jul 25 to discuss trade issues. The focus will be on auto tariffs and it is unclear whether the EU will make an offer which will satisfy the U.S. President.
Biotechs Safe in this Scenario
On Jul 24, the Nasdaq Biotechnology Index (IBB) hit a fresh 52-week high. The index is up nearly 8% year to date and its components seem to be insulated from trade tensions. This is because healthcare is essentially a non-tradeable activity. The only threat to the sector at this point is a possible step-up in political rhetoric ahead of the midterm elections in November.
Most of this rhetoric will be focus on drug-pricing, an issue which caught the imagination of contestants in the last presidential elections. Since then, Trump has made occasional remarks on this topic. But concrete action on this front has been far from forthcoming.
The only factors that actually influence biotech stocks are the advances made in research and development. The sectors recently received impetus from encouraging trial results announced by Biogen. The biotech major has taken giant steps toward combating the dreaded Alzheimer's disease. More such developments will only attract greater investor attention to the biotech arena.
Our Choices
President Trump seems determined to persevere with his fiercely protectionist trade policy. Further, the Trump administration’s recent actions mean that it intends to act upon its rhetoric, which continues to flow uninterrupted.
In this scenario, it makes for a smart move to invest in biotech stocks, a domain which is largely insulated from trade tensions. We have narrowed our search to the following stocks based on a Zacks Rank #1 (Strong Buy) and other relevant metrics. You can see the complete list of today’s Zacks #1 Rank stocks here.
Illumina, Inc. is a life sciences company that provides tools and integrated systems for analysis of genetic variation and function.
Illumina’s expected earnings growth for the current year is 21.7%. The Zacks Consensus Estimate for the current year has improved by 0.2% over the last 30 days.
Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases.
Ultragenyx’s expected earnings growth for the current year is 29.4%. The Zacks Consensus Estimate for the current year has improved by 0.5% over the last 30 days.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company.
Xenon’s expected earnings growth for the current year is 17.3%. The Zacks Consensus Estimate for the current year has improved by 3.6% over the last 30 days.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders
Vanda’s projected growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has improved by 11.1% over the last 60 days.
Pharming Group N.V. develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products.
Pharming Group’s projected growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has improved by 6.3% over the last 30days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
For Immediate Release
Chicago, IL – July 26, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Illumina, Inc. (ILMN - Free Report) , Ultragenyx Pharmaceutical Inc. (RARE - Free Report) , Xenon Pharmaceuticals Inc. (XENE - Free Report) , Vanda Pharmaceuticals Inc. (VNDA - Free Report) and Pharming Group N.V. (PHGUF - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday’s Analyst Blog:
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
On Jul 24, President Trump tweeted protectionist rhetoric once again, claiming that “Tariffs are the greatest!” He believes that they are an effective bargaining tool which can force countries to negotiate more equitable trade agreements. At this point, the Trump administration has imposed tariffs on Chinese imports worth $34 billion and more such levies are likely to follow.
Though markets are now choosing to focus on the ongoing earnings, they have been rattled by such moves in the past. It is unlikely that this trend will be disrupted in the near future. Investors, are, therefore, constantly on the lookout for investments which can provide both protection and profits in such a scenario.
Incidentally, biotech stocks are largely resilient to trade-related disruptions. Healthcare is a non-tradeable activity and its fortunes are dictated by the furious pace of advancements in this area. Given the current market backdrop, it makes good sense to invest in biotech stocks at this point.
Trump Maintains Protectionist Stance
Trump’s latest remarks are similar to tweets made earlier in March, when he claimed that “trade wars are good, and easy to win.” Apart from the tariffs imposed on $34 billion worth of Chinese goods, the Trump administration will also shortly impose tariffs on goods worth an additional $16 billion. Trump is also considering imposing tariffs on an additional $200 billion of Chinese imports.
And that’s not all. In an interview with CNBC on Jul 19, the President said that he may even impose tariffs on an additional $505 billion of Chinese imports. Meanwhile, Trump is slated to meet European Commission President Jean-Claude Juncker on Jul 25 to discuss trade issues. The focus will be on auto tariffs and it is unclear whether the EU will make an offer which will satisfy the U.S. President.
Biotechs Safe in this Scenario
On Jul 24, the Nasdaq Biotechnology Index (IBB) hit a fresh 52-week high. The index is up nearly 8% year to date and its components seem to be insulated from trade tensions. This is because healthcare is essentially a non-tradeable activity. The only threat to the sector at this point is a possible step-up in political rhetoric ahead of the midterm elections in November.
Most of this rhetoric will be focus on drug-pricing, an issue which caught the imagination of contestants in the last presidential elections. Since then, Trump has made occasional remarks on this topic. But concrete action on this front has been far from forthcoming.
The only factors that actually influence biotech stocks are the advances made in research and development. The sectors recently received impetus from encouraging trial results announced by Biogen. The biotech major has taken giant steps toward combating the dreaded Alzheimer's disease. More such developments will only attract greater investor attention to the biotech arena.
Our Choices
President Trump seems determined to persevere with his fiercely protectionist trade policy. Further, the Trump administration’s recent actions mean that it intends to act upon its rhetoric, which continues to flow uninterrupted.
In this scenario, it makes for a smart move to invest in biotech stocks, a domain which is largely insulated from trade tensions. We have narrowed our search to the following stocks based on a Zacks Rank #1 (Strong Buy) and other relevant metrics. You can see the complete list of today’s Zacks #1 Rank stocks here.
Illumina, Inc. is a life sciences company that provides tools and integrated systems for analysis of genetic variation and function.
Illumina’s expected earnings growth for the current year is 21.7%. The Zacks Consensus Estimate for the current year has improved by 0.2% over the last 30 days.
Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases.
Ultragenyx’s expected earnings growth for the current year is 29.4%. The Zacks Consensus Estimate for the current year has improved by 0.5% over the last 30 days.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company.
Xenon’s expected earnings growth for the current year is 17.3%. The Zacks Consensus Estimate for the current year has improved by 3.6% over the last 30 days.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders
Vanda’s projected growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has improved by 11.1% over the last 60 days.
Pharming Group N.V. develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products.
Pharming Group’s projected growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has improved by 6.3% over the last 30days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.